Écrit par Pluristem | 01 Mai 2012

HAIFA, ISRAEL, April 30, 2012 -- Pluristem Therapeutics Inc. (NasdaqCM:PSTI; TASE: PLTR) today announced that its wholly owned subsidiary, Pluristem Ltd., has received approval for a 11.8 million New Israeli Shekels (approximately $3.1 million) grant from the Office of the Chief Scientist (OCS) within the Israeli Ministry of Industry, Trade and Labor. Once received, the grant will be used...

Écrit par GlobalData | 18 Avril 2012

LONDON, UK (GlobalData), 18 April 2012 - China and India are set to dominate the immunochemistry diagnostics market, according to a new report by medical intelligence company GlobalData.

The new report* found that the US presently takes monopoly in the immunochemistry market, largely due to above-average testing for drug abuse. However, emerging countries are anticipated to rise up and...

Écrit par Pluristem | 03 Avril 2012

A Team of Internationally Renowned Physicians Will Collaborate on Advancing PLX Cell Therapies for Millions of People Suffering from the Chronic Disease



HAIFA, ISRAEL, April 3, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR) today announced that it has formed a steering committee to assist in advancing PLacental eXpanded (PLX) cell therapies for the treatment of...

Écrit par JS Bio | 29 Mars 2012

N°1 dans le Var, N°2 dans le Vaucluse et N°3 dans les Bouches-du-Rhône en nombre de laboratoires, JS BIO s’est hissé en 2 ans au rang de leader des acteurs de la biologie médicale en PACA. Cette structure fédérative de biologistes réunira 44 laboratoires fin mars et s’impose d’ores et déjà comme un acteur de la santé emblématique en matière de qualité et de niveau de...